Description: Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused on the development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.
Home Page: www.calliditas.se
CALT Technical Analysis
Kungsbron 1, D5
Stockholm,
111 22
Sweden
Phone:
46 84 11 30 05
Officers
| Name | Title |
|---|---|
| Ms. Renee Aguiar-Lucander | Chief Exec. Officer |
| Mr. Fredrik Johansson | Chief Financial Officer |
| Dr. Katayoun Welin-Berger Ph.D. | VP of Operations |
| Dr. Johan Haggblad Ph.D. | Chief Scientific Officer |
| Mr. Mikael Widell | Head of Communications & IR |
| Mr. Jonathan A. Schur | Group Gen. Counsel |
| Ms. Sandra Frithiof | Head of HR |
| Ms. Ann-Kristin Myde BSc | Head of Clinical Devel. & VP of Project Management |
| Mr. Andrew B. Udell B.Sc., M.B.A. | Pres of North America Commercial |
| Dr. Krassimir Mitchev | Head of Medical Affairs |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 8.7719 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.3857 |
| Price-to-Sales TTM: | 13.2379 |
| IPO Date: | 2020-06-05 |
| Fiscal Year End: | December |
| Full Time Employees: | 98 |